GenomeScan will be at the Molecular Analysis for Precision Oncology Congress 2023 (MAP), organized by the European Society for Medical Oncology (ESMO). MAP 2023 takes place on 4-6 October in Paris, France.
Precision oncology and translational research are fast evolving fields that have entered the mainstream of clinical practice. By attending MAP, we look forward to gaining deeper insights into precision medicine, cancer-stromal interactions, clonal evolution, metastatic dissemination and drug response and resistance.
Why meet GenomeScan?
GenomeScan is a Next Generation Sequencing (NGS) service provider, offering customizable solutions to pharmaceutical and biotechnology companies, as well as to healthcare providers and academic institutions. Leveraging state-of-the-art next generation sequencing technologies and advanced bioinformatics analysis, we uncover critical genetic alterations, including mutations, copy number variations, and structural variants. With a focus on accuracy, reliability, and personalized support, GenomeScan empowers researchers and clinicians to make informed decisions in diagnosis, treatment selection, and patient management, ultimately driving advancements in precision oncology.
Our services that can help your next oncology project include:
- Comprehensive cancer panel
- Patient stratification in clinical trials
- Genetics and transcriptomics
- RNA sequencing of FFPE samples
Feel free to reach out to our Head of Oncology, Stefanie Klaver-Flores, who will be attending MAP 2023 and will be happy to connect with you. You can send her a message at oncology@genomescan.nl.
About the Molecular Analysis for Precision Oncology Congress 2023 (MAP)
ESMO, European Society for Medical Oncology, aims is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. In line with this mission, MAP 2023 promises insights into the molecular characterisation and clonal evolution of solid tumours on different cancer populations, emerging technologies for cancer profiling, including artificial intelligence and data analysis, mechanisms driving tumour expansion, metastatic dissemination and cross talk between malignancy, microenvironment and host, and molecular tumour classification and biomarker-driven development of targeted therapeutics with their methodological and regulatory implications. Our highlights of MAP 2023 lecture topics include:
- Tumor microenvironment
- Immunotherapy
- Biomarker driven drug development
- Pan-cancer clinical trials
We look forward to connecting with you at the MAP 2023!
